Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is developing various biologics product candidates, including Burosumab, a human monoclonal antibody that is in Phase III study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It is also developing a range of small-molecule product candidates, such as UX007, a substrate replacement therapy that completed Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome. In addition, the company is developing adeno-associated virus 8 (AAV8) gene therapy products comprising DTX301, an AAV8 for the treatment of OTC deficiency; DTX401, an AAV8 gene therapy program for the treatment of patients with GSDIa; and DTX201, a FVIII gene therapy program for the treatment of hemophilia A. It has a collaboration agreement with Rentschler Fill Solutions GmbH. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RARE
Previous Symbol
CUSIPN/A
Phone415-483-8800
Debt
Debt-to-Equity RatioN/A
Current Ratio8.51
Quick Ratio8.43
Price-To-Earnings
Trailing P/E Ratio-6.13
Forward P/E Ratio-11.53
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.61 million
Price / Sales891.64
Cash FlowN/A
Price / Cash FlowN/A
Book Value$8.68 per share
Price / Book5.30
Profitability
EPS (Most Recent Fiscal Year)($7.50)
Net Income$-302,130,000.00
Net Margins-508.70%
Return on Equity-40.10%
Return on Assets-34.46%
Miscellaneous
Employees520
Outstanding Shares50,580,000
Market Cap$2.33 billion
OptionableOptionable
Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions
What is Ultragenyx Pharmaceutical's stock symbol?
Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."
How were Ultragenyx Pharmaceutical's earnings last quarter?
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) released its earnings results on Monday, November, 5th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($1.94) by $0.20. The biopharmaceutical company earned $11.80 million during the quarter, compared to analyst estimates of $11.97 million. Ultragenyx Pharmaceutical had a negative return on equity of 40.10% and a negative net margin of 508.70%. The company's revenue for the quarter was up 5800.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.87) earnings per share. View Ultragenyx Pharmaceutical's Earnings History.
When is Ultragenyx Pharmaceutical's next earnings date?
What price target have analysts set for RARE?
18 brokers have issued twelve-month target prices for Ultragenyx Pharmaceutical's stock. Their forecasts range from $54.00 to $95.00. On average, they anticipate Ultragenyx Pharmaceutical's stock price to reach $75.3125 in the next twelve months. This suggests a possible upside of 63.7% from the stock's current price. View Analyst Price Targets for Ultragenyx Pharmaceutical.
What is the consensus analysts' recommendation for Ultragenyx Pharmaceutical?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ultragenyx Pharmaceutical.
What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock?
Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:
- 1. According to Zacks Investment Research, "Ultragenyx is encouraged by the growing demand for Crysvita from both children and adults with X-linked hypophosphatemia (XLH) inthe United States. During the third quarter, Mepsevii received European approval under exceptional circumstances for the treatment of non-neurological manifestations of MPS VII.In 2019, the company expects to file for potential approval of its third therapy, UX007 in fatty acid oxidation disorders. Ultragenyx continues to advance its two gene therapy clinical programs —DTX401 for glycogen storage disease type Ia and DTX301 for ornithine transcarbamylase deficiency—with additional data expected around the end of 2018 and in 2019 respectively. However, the company plans to discontinue the study, evaluating UX007 in patients with Glut1 DS, as it did not achieve its primary endpoint, which is a setback for the company. Shares of the company has outperformed the industry, year to date." (12/13/2018)
- 2. JPMorgan Chase & Co. analysts commented, "Ahead of the pending Phase 3 results for UX007 (trihep) in Glut1 DS expected sometime this quarter, we sifted through early data and market sizing assumptions to frame expectations and potential upside/downside on the event. Bottom line, while directly comparable data are limited to say the least (most similar pilot study only had an N of 6 and Phase 2 trials evaluated different endpoints), we believe a positive read- out is the most likely outcome given proof of concept data combined with seemingly reasonable powering assumptions. Between the recent pullback in shares (15% since 9/25) and our sense that this opportunity is not well understood by the market, we see risk/reward slightly skewed to the upside. Maintain OW." (10/7/2018)
Has Ultragenyx Pharmaceutical been receiving favorable news coverage?
Headlines about RARE stock have been trending somewhat positive on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ultragenyx Pharmaceutical earned a news impact score of 1.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are some of Ultragenyx Pharmaceutical's key competitors?
Some companies that are related to Ultragenyx Pharmaceutical include Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Ionis Pharmaceuticals (IONS), Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), GALAPAGOS NV/S (GLPG), Amarin (AMRN), Alkermes (ALKS), Catalent (CTLT), Amneal Pharmaceuticals (AMRX) and SAGE Therapeutics (SAGE).
Who are Ultragenyx Pharmaceutical's key executives?
Ultragenyx Pharmaceutical's management team includes the folowing people:
- Dr. Emil D. Kakkis, Pres, CEO & Director (Age 58)
- Ms. Shalini Sharp, CFO & Exec. VP (Age 43)
- Mr. Thomas R. Kassberg, Chief Bus. Officer & Exec. VP (Age 58)
- Mr. John Richard Pinion II, Chief Quality Officer & Exec. VP of Translational Sciences (Age 52)
- Dr. Wladimir Hogenhuis, Chief Operating Officer
Who are Ultragenyx Pharmaceutical's major shareholders?
Ultragenyx Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (11.58%), Capital International Investors (8.62%), BlackRock Inc. (8.68%), Vanguard Group Inc. (8.01%), Vanguard Group Inc (8.01%) and FMR LLC (6.63%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.
Which institutional investors are selling Ultragenyx Pharmaceutical stock?
RARE stock was sold by a variety of institutional investors in the last quarter, including Brown Advisory Inc., FMR LLC, AXA, Teachers Advisors LLC, Deutsche Bank AG, Pictet Asset Management Ltd., Sector Gamma AS and TIAA CREF Investment Management LLC. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Insider Buying and Selling for Ultragenyx Pharmaceutical.
Which institutional investors are buying Ultragenyx Pharmaceutical stock?
RARE stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Capital World Investors, First Trust Advisors LP, Macquarie Group Ltd., Capital Research Global Investors, Federated Investors Inc. PA, Dimensional Fund Advisors LP and Clearbridge Investments LLC. View Insider Buying and Selling for Ultragenyx Pharmaceutical.
How do I buy shares of Ultragenyx Pharmaceutical?
Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ultragenyx Pharmaceutical's stock price today?
One share of RARE stock can currently be purchased for approximately $46.01.
How big of a company is Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical has a market capitalization of $2.33 billion and generates $2.61 million in revenue each year. The biopharmaceutical company earns $-302,130,000.00 in net income (profit) each year or ($7.50) on an earnings per share basis. Ultragenyx Pharmaceutical employs 520 workers across the globe.
What is Ultragenyx Pharmaceutical's official website?
How can I contact Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]
MarketBeat Community Rating for Ultragenyx Pharmaceutical (NASDAQ RARE)
MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe RARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
